Hello,
Welcome to Insider
- Verily's new president of research spoke to Insider about her new plan to expand clinical trial support;
- Peloton is rebranding itself as a corporate wellness company;
- Flu shots have gotten political since the COVID-19 pandemic.
If you're new to this
How Amy Abernethy is rejiggering one of Verily's biggest bets to change clinical research and propel the Google spin-off into the future
- The
Google spin-offVerily is looking to expand its clinical-trials business. - Dr. Amy Abernethy, Verily's new president of research, shared the vision for 2022 in an interview.
- The venture will sell more trial tools but also build a massive data resource to help drugmakers.
Peloton's been hit hard as interest in home exercise drops. Here's why it's starting to sell its services to companies like Samsung and UnitedHealthcare.
Peloton 's stock price is underperforming investors' expectations after pandemic highs.- One revenue stream the company is considering is its young corporate-wellness arm.
- Peloton provides benefits to companies like Samsung and thinks its community gives it an edge.
The gap between Republicans and Democrats on flu shots is 20 percentage-points bigger than it was pre-pandemic
- Recent polls show a 25 percentage-point gap between Republicans and Democrats who've gotten or will get a
flu shot . - This is remarkably similar to the approximately 30 percentage-point partisan gap on COVID-19 vaccine uptake.
- Prior to the COVID-19 pandemic, there was little to no partisan gap on influenza vaccine uptake.
More stories we're reading:
- We asked 9 of Europe's top healthcare investors which areas would affect the industry most amid record VC funding (Insider)
- A company in the UK will soon start clinical trials of a vaccine patch that could stimulate T-cell immunity (The Guardian)
- Goop threw a cruise, and no Goopies came (Insider)
- Scientists have found a second person who has been 'naturally' cured of HIV (STAT News)
-Leah